Developer docs
API playgroundTry for free, no card

Search company profiles

SciBase

Full company profile

uuid00022jj

Namestring
SciBase
Legal namestring
SciBase Holding AB
Websiteurl
scibase.com
Company typeenum
Public
Founded yearint
1998
Descriptiontext

SciBase Holding AB is a Swedish medical technology company founded in 1998 and listed on Nasdaq First North Growth Market under the ticker sto:SCIB. The company develops and commercializes Nevisense, an FDA-approved and CE-marked diagnostic device based on Electrical Impedance Spectroscopy (EIS) technology that provides objective diagnostic data for melanoma and non-melanoma skin cancer detection. The platform analyzes electrical impedance measurements from skin tissue to support clinical decisions in dermatology, with the technology included in US NCCN Clinical Practice Guidelines for Melanoma and over 400,000 tests sold globally. SciBase is expanding the platform's clinical applications into atopic dermatitis prediction in newborns, age-related skin barrier assessment, and detection of chemical-induced skin barrier damage, supported by a portfolio of research collaborations with institutions including Mount Sinai, UCSF, and the Swiss Institute of Allergy and Asthma Research.

The company operates a hybrid hardware-and-consumables revenue model: Nevisense devices are sold to dermatology clinics and healthcare systems in the US and European markets, while single-use electrodes generate recurring revenue, with Q1 2026 electrode sales volume of 30,460 units (up 70% YoY). SciBase has an expanded collaboration and license agreement with Castle Biosciences that includes a SEK 20 million loan convertible to equity, and the company is pursuing US market expansion funded by a SEK 83 million rights issue completed in early 2026. Distribution is primarily through direct enterprise field sales targeting dermatologists and healthcare providers, with expanded labeling now allowing physician assistants and medical assistants to perform the procedure. FY 2025 net sales totaled TSEK 40,461 (up 36% YoY), with Q1 2026 revenue of TSEK 14,278 (up 61% YoY), while the company reported a FY 2025 loss of TSEK 87,063 reflecting continued investment in commercialization and clinical development.

Short descriptiontext

SciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, serving dermatology clinics and healthcare providers in the US and European markets through direct enterprise sales and a recurring electrode consumable model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSundbyberg, Sweden
HQ citystring
Sundbyberg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermatology diagnostics, melanoma detection devices, medical technology hardware, skin barrier assessment, electrochemical diagnostics
Industry2 codes
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAKACAC
Dermatopathology
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Dermatology Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Nevisense Device Sales
TypeHardware Sales
Description

Sale of the Nevisense hardware device to dermatology clinics and healthcare systems for melanoma detection and skin barrier assessment.

prnewswire.com
2Electrode/Test Consumables
TypeUsage Based
Description

Recurring sales of electrodes for the Nevisense device. Q1 2026 saw 70% increase in electrode sales volume reaching 30,460 units.

prnewswire.com
3Licensing and Collaboration Revenue
TypeLicensing Royalties
Description

Expanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders, including loan agreement of SEK 20 million with potential conversion to equity.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Nevisense
Description

Electrical Impedance Spectroscopy (EIS) diagnostic device for melanoma detection and skin barrier assessment

prnewswire.com
Core offering1 text field

SciBase develops, manufactures, and commercializes the Nevisense medical diagnostic device, an FDA-approved and CE-marked platform based on Electrical Impedance Spectroscopy (EIS) for melanoma and non-melanoma skin cancer detection. The company sells the Nevisense hardware together with single-use electrodes as recurring consumables to dermatology clinics and healthcare providers, and has expanded applications to atopic dermatitis prediction and skin barrier assessment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Melanoma detection accuracy improved with statistically significant and clinically meaningful results over visual assessment and dermoscopy alone
+4 more records
Product overview1 text field

SciBase offers the Nevisense platform, a medical diagnostic system based on Electrical Impedance Spectroscopy (EIS) technology. The core Nevisense device is an FDA-approved and CE-marked in-vitro diagnostic tool primarily used for melanoma and non-melanoma skin cancer detection, with expanding applications in atopic dermatitis prediction and assessment. The company sells the device along with single-use electrodes as consumables. The EIS technology provides objective, quantitative measurements that complement visual assessment and dermoscopy, enabling clinicians to make more informed early detection decisions.

Product and service1 record
1Nevisense Device
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

DETECT-AD clinical study - multicenter prospective trial to assess ability of SciBase's EIS technology to predict flares in atopic dermatitis. Aims to shift treatment from reactive to proactive care.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Research collaboration demonstrating that Nevisense measurements taken within first days of life can identify infants who later develop atopic dermatitis during their first year. Study published in journal Allergy.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Ex-vivo study demonstrating Nevisense can detect skin barrier disruption caused by surfactants in household cleaning products. Results published in Allergy journal.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Research collaboration at Society for Investigative Dermatology Annual Meeting demonstrating Nevisense's ability to detect and quantify age-related changes in skin barrier. Cross-sectional study compared EIS measurements between young and older adults.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-07
Description

Expanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders. Includes SEK 20 million loan agreement with potential conversion to equity to support production ramp-up and growth. Collaboration initiated June 2025 and expanded November 2025.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-06-30
Description

Advisory support for directed share issue transaction.

7Advokatfirman Schjødt
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-06-30
Description

Legal advisory support for directed share issue transaction.

news.cision.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Castle Biosciences develops molecular diagnostic tests for dermatologic conditions including DecisionDx-Melanoma and is SciBase's collaboration partner on the DETECT-AD atopic dermatitis program. Directly comparable as both target the dermatology diagnostic decision point, though Castle operates in genomics rather than impedance spectroscopy.

TypeDirect peer
Description

DermTech offers the Pigmented Lesion Assay, a non-invasive adhesive patch genomic test for melanoma. Directly competes with Nevisense at the melanoma detection decision point, targeting the same dermatology clinicians with an alternative non-visual diagnostic technology.

TypeEmerging player
Description

SkinVision provides an AI-driven smartphone application for skin cancer risk assessment. Competes with Nevisense at the early melanoma triage stage using a lower-friction, lower-cost consumer-grade modality rather than a clinical device.

TypeDirect peer
Description

FotoFinder manufactures dermoscopy and total body photography systems used in dermatology clinics for melanoma screening. Targets the same dermatologists as Nevisense but with imaging-based rather than impedance-based diagnostics.

TypeDirect peer
Description

Canfield Scientific provides VECTRA whole-body imaging and DermaGraphix software for dermatology practices. Sells complementary melanoma-screening technology to the same dermatology clinic channel as Nevisense.

TypeDirect peer
Description

DermLite designs and manufactures handheld dermatoscopes widely used by dermatologists for melanoma screening. Represents the incumbent visual/dermoscopy standard against which Nevisense claims statistically significant improvement.

TypeDirect peer
Description

Heine is a leading manufacturer of dermatoscopes and dermatological diagnostic instruments. Competes with Nevisense in dermatology clinics as a long-established provider of skin cancer diagnostic hardware.

TypeEmerging player
Description

Michelson Diagnostics develops VivaScope confocal microscopy for non-invasive skin imaging. Addresses the same dermatology diagnostic workflow as Nevisense with optical rather than electrical measurement technology.

TypeEmerging player
Description

Skin Analytics offers an AI-based dermatology decision support tool (DERM) approved in the UK for skin cancer triage. Emerging alternative to Nevisense leveraging AI image analysis rather than impedance spectroscopy.

TypeBroad incumbent
Description

Strata Skin Sciences markets dermatology diagnostic and therapeutic devices including the VTRAC excimer lamp. Broader dermatology device incumbent with overlapping physician customer base but focused on treatment rather than melanoma detection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SciBase

Dermatology Medical Devicesscibase.com

SciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, serving dermatology clinics and healthcare providers in the US and European markets through direct enterprise sales and a recurring electrode consumable model.

What SciBase does

SciBase Holding AB is a Swedish medical technology company founded in 1998 and listed on Nasdaq First North Growth Market under the ticker sto:SCIB. The company develops and commercializes Nevisense, an FDA-approved and CE-marked diagnostic device based on Electrical Impedance Spectroscopy (EIS) technology that provides objective diagnostic data for melanoma and non-melanoma skin cancer detection. The platform analyzes electrical impedance measurements from skin tissue to support clinical decisions in dermatology, with the technology included in US NCCN Clinical Practice Guidelines for Melanoma and over 400,000 tests sold globally. SciBase is expanding the platform's clinical applications into atopic dermatitis prediction in newborns, age-related skin barrier assessment, and detection of chemical-induced skin barrier damage, supported by a portfolio of research collaborations with institutions including Mount Sinai, UCSF, and the Swiss Institute of Allergy and Asthma Research.

The company operates a hybrid hardware-and-consumables revenue model: Nevisense devices are sold to dermatology clinics and healthcare systems in the US and European markets, while single-use electrodes generate recurring revenue, with Q1 2026 electrode sales volume of 30,460 units (up 70% YoY). SciBase has an expanded collaboration and license agreement with Castle Biosciences that includes a SEK 20 million loan convertible to equity, and the company is pursuing US market expansion funded by a SEK 83 million rights issue completed in early 2026. Distribution is primarily through direct enterprise field sales targeting dermatologists and healthcare providers, with expanded labeling now allowing physician assistants and medical assistants to perform the procedure. FY 2025 net sales totaled TSEK 40,461 (up 36% YoY), with Q1 2026 revenue of TSEK 14,278 (up 61% YoY), while the company reported a FY 2025 loss of TSEK 87,063 reflecting continued investment in commercialization and clinical development.

SciBase firmographics

Firmographics
Name
SciBase
Legal name
SciBase Holding AB
Website
https://scibase.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
SciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, serving dermatology clinics and healthcare providers in the US and European markets through direct enterprise sales and a recurring electrode consumable model.
Ownership category
akta.pro rank

SciBase industry classification

Industry
Product category
Dermatology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAKACAC
Dermatopathology

Keywords

  • Dermatology diagnostics
  • Melanoma detection devices
  • Medical technology hardware
  • Skin barrier assessment
  • Electrochemical diagnostics

Where SciBase is headquartered

Location

Headquarters

HQ city
Sundbyberg
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

SciBase business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Nevisense Device Sales: Sale of the Nevisense hardware device to dermatology clinics and healthcare systems for melanoma detection and skin barrier assessment.
  2. Electrode/Test Consumables: Recurring sales of electrodes for the Nevisense device. Q1 2026 saw 70% increase in electrode sales volume reaching 30,460 units.
  3. Licensing and Collaboration Revenue: Expanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders, including loan agreement of SEK 20 million with potential conversion to equity.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

SciBase product offering

Product offering

Core offering

SciBase develops, manufactures, and commercializes the Nevisense medical diagnostic device, an FDA-approved and CE-marked platform based on Electrical Impedance Spectroscopy (EIS) for melanoma and non-melanoma skin cancer detection. The company sells the Nevisense hardware together with single-use electrodes as recurring consumables to dermatology clinics and healthcare providers, and has expanded applications to atopic dermatitis prediction and skin barrier assessment.

Product overview

SciBase offers the Nevisense platform, a medical diagnostic system based on Electrical Impedance Spectroscopy (EIS) technology. The core Nevisense device is an FDA-approved and CE-marked in-vitro diagnostic tool primarily used for melanoma and non-melanoma skin cancer detection, with expanding applications in atopic dermatitis prediction and assessment. The company sells the device along with single-use electrodes as consumables. The EIS technology provides objective, quantitative measurements that complement visual assessment and dermoscopy, enabling clinicians to make more informed early detection decisions.

Differentiator

Problem solved

Functional benefit

Brands

  • Nevisense: Electrical Impedance Spectroscopy (EIS) diagnostic device for melanoma detection and skin barrier assessment

Products and services

  • Nevisense Device

Quantifiable outcome

  • Melanoma detection accuracy improved with statistically significant and clinically meaningful results over visual assessment and dermoscopy alone
  • +4 more outcomes

Companies that use SciBase

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

SciBase technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

SciBase partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • Castle Biosciences (DETECT-AD Study)coreStrategic or Co-development Partner · 10 June 2026DETECT-AD clinical study - multicenter prospective trial to assess ability of SciBase's EIS technology to predict flares in atopic dermatitis. Aims to shift treatment from reactive to proactive care.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 9 June 2026Research collaboration demonstrating that Nevisense measurements taken within first days of life can identify infants who later develop atopic dermatitis during their first year. Study published in journal Allergy.
  • Swiss Institute of Allergy and Asthma Research (SIAF)majorStrategic or Co-development Partner · 28 May 2026Ex-vivo study demonstrating Nevisense can detect skin barrier disruption caused by surfactants in household cleaning products. Results published in Allergy journal.
  • UCSF (University of California, San Francisco)majorStrategic or Co-development Partner · 18 May 2026Research collaboration at Society for Investigative Dermatology Annual Meeting demonstrating Nevisense's ability to detect and quantify age-related changes in skin barrier. Cross-sectional study compared EIS measurements between young and older adults.
  • Castle BiosciencescoreStrategic or Co-development Partner · 7 November 2025Expanded collaboration and license agreement with Castle Biosciences for development of diagnostic tests for skin disorders. Includes SEK 20 million loan agreement with potential conversion to equity to support production ramp-up and growth. Collaboration initiated June 2025 and expanded November 2025.
  • Vator SecuritiesminorImplementation/ SI/ Consulting Partner · 30 June 2025Advisory support for directed share issue transaction.
  • Advokatfirman SchjødtminorImplementation/ SI/ Consulting Partner · 30 June 2025Legal advisory support for directed share issue transaction.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

SciBase competitors and assessment

Company assessment

Direct peers

  • Castle Biosciences: Castle Biosciences develops molecular diagnostic tests for dermatologic conditions including DecisionDx-Melanoma and is SciBase's collaboration partner on the DETECT-AD atopic dermatitis program. Directly comparable as both target the dermatology diagnostic decision point, though Castle operates in genomics rather than impedance spectroscopy.
  • DermTech: DermTech offers the Pigmented Lesion Assay, a non-invasive adhesive patch genomic test for melanoma. Directly competes with Nevisense at the melanoma detection decision point, targeting the same dermatology clinicians with an alternative non-visual diagnostic technology.
  • FotoFinder Systems: FotoFinder manufactures dermoscopy and total body photography systems used in dermatology clinics for melanoma screening. Targets the same dermatologists as Nevisense but with imaging-based rather than impedance-based diagnostics.
  • Canfield Scientific: Canfield Scientific provides VECTRA whole-body imaging and DermaGraphix software for dermatology practices. Sells complementary melanoma-screening technology to the same dermatology clinic channel as Nevisense.
  • DermLite: DermLite designs and manufactures handheld dermatoscopes widely used by dermatologists for melanoma screening. Represents the incumbent visual/dermoscopy standard against which Nevisense claims statistically significant improvement.
  • Heine Optotechnik: Heine is a leading manufacturer of dermatoscopes and dermatological diagnostic instruments. Competes with Nevisense in dermatology clinics as a long-established provider of skin cancer diagnostic hardware.

Emerging players

  • SkinVision: SkinVision provides an AI-driven smartphone application for skin cancer risk assessment. Competes with Nevisense at the early melanoma triage stage using a lower-friction, lower-cost consumer-grade modality rather than a clinical device.
  • Michelson Diagnostics: Michelson Diagnostics develops VivaScope confocal microscopy for non-invasive skin imaging. Addresses the same dermatology diagnostic workflow as Nevisense with optical rather than electrical measurement technology.
  • Skin Analytics: Skin Analytics offers an AI-based dermatology decision support tool (DERM) approved in the UK for skin cancer triage. Emerging alternative to Nevisense leveraging AI image analysis rather than impedance spectroscopy.

Broad incumbents

  • Strata Skin Sciences: Strata Skin Sciences markets dermatology diagnostic and therapeutic devices including the VTRAC excimer lamp. Broader dermatology device incumbent with overlapping physician customer base but focused on treatment rather than melanoma detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SciBase social profiles

Digital presence

SciBase compliance and trust

Trust signal

Compliance2 records

SciBase financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SciBase leadership team

Management profile

Number of profiles

Profiles5 records

SciBase funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SciBase M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SciBase

What does SciBase do?

SciBase develops, manufactures, and commercializes the Nevisense medical diagnostic device, an FDA-approved and CE-marked platform based on Electrical Impedance Spectroscopy (EIS) for melanoma and non-melanoma skin cancer detection. The company sells the Nevisense hardware together with single-use electrodes as recurring consumables to dermatology clinics and healthcare providers, and has expanded applications to atopic dermatitis prediction and skin barrier assessment.

Is SciBase a public or private company?

SciBase is a public company. It is classified as public and is currently operating.

When was SciBase founded?

SciBase was founded in 1998. It employs 51 to 100 people.

Where is SciBase based?

SciBase is headquartered in Sundbyberg, Sweden, in the Europe region.

How does SciBase make money?

Three revenue lines are on record. Nevisense Device Sales are the primary driver. The others are electrode/Test Consumables and licensing and Collaboration Revenue.

Who are SciBase's main competitors?

Direct peers on record are Castle Biosciences, DermTech, FotoFinder Systems, Canfield Scientific, DermLite and Heine Optotechnik. Emerging players are SkinVision, Michelson Diagnostics and Skin Analytics. Strata Skin Sciences is listed as a broad incumbent.

Does SciBase have an API?

No public API is recorded for SciBase.

What industry is SciBase in?

SciBase's product category is Dermatology Medical Devices. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAKACAC, Dermatopathology. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Third NewsSciBase Holding Appoints Nomination Committee for Upcoming AGM in 2027SciBase Holding appointed a new nominating committee for its May 20, 2027 AGM, with members including Anders Bladh, Derek Maetzold, Maria Anderkvist, and Jesper Høiland. Shareholders may submit agenda proposals to the board by seven weeks before the meeting.The future of tradingSciBase Holding Announces Annual General MeetingSciBase Holding will hold its annual general meeting on May 20, 2027, in Stockholm. The meeting is scheduled for that date, with no further details provided.The future of tradingSciBase Announces Nevisense Use in NIH-Led Study of Environmental Exposure Effects on SkinSciBase announced a planned NIH-led study with the Swiss Institute of Allergy and Asthma Research to assess environmental exposure effects on skin, using Nevisense as a primary outcome measure. Findings remain prospective, and a deeper collaboration with Castle Biosciences generated an additional order worth about SEK 5 million for another clinical study.TradingViewSCIB: Sales growth and U.S. reimbursement gains contrast with persistent losses and funding uncertaintySciBase Holding AB reported Q3 revenue growth of 41%, driven by U.S. and German skin-cancer demand, with improved gross margin. The company's first U.S. private reimbursement expands commercial opportunity, but continued losses and financing needs leave material going-concern uncertainty.PR NewswireSciBase has secured first US payer coverage with major insurance company, aims for global lead in non-invasive skin assessmentSciBase Holding AB secured its first US payer coverage with a major insurance company for its Nevisense non-invasive skin assessment device. The policy covers EIS for atypical pigmented lesions, and the company aims to capture a significant share of a $1 billion market with a 75% gross margin target.PR NewswireSciBase has secured first US payer coverage with major insurance company, aims for global lead in non-invasive skin assessmentSciBase Holding AB secured its first US payer coverage with a major private insurance company for its Nevisense non-invasive skin assessment device. The policy covers EIS for atypical pigmented lesions, and the company aims to capture a significant share of a $1 billion market with a 75% gross margin target.TradingViewSciBase Holding AB (SCIB) Wins First US Payer Coverage for NevisenseSciBase Holding AB secured its first US private insurer medical policy covering Nevisense EIS (CPT 0658T) for evaluating suspicious pigmented lesions when biopsy is considered. The coverage targets melanoma workups, with a market size estimated at $1B and a gross margin target of 75%.PRESSBEESciBases EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study ...Middle EastSciBase Holding AB announced a new study collaboration between the NIH and a Swiss entity, with its EIS technology selected as the primary endpoint. The study aims to advance AI-based dermatology detection and prevention. The announcement was published on PR Newswire.TradingViewSciBase Holding AB (SCIB) Named Primary Endpoint in NIH-Led Skin StudySciBase Holding AB said its Nevisense EIS technology will serve as a primary endpoint in an NIH-led study on environmental exposure effects on skin barrier function. The study compares synthetic surfactants and cotton, with collaboration from SIAF. The AI analyst view notes this is early-stage validation, not immediate revenue impact.YahooSciBase's rights issue registered, conversion of BTA into sharesSciBase Holding AB registered its rights issue with the Swedish Companies Registration Office on 8 October 2026, issuing 3,834,487 new shares. The BTA allotted in the rights issue will convert into shares, with trading in BTA ending 16 October and new shares available 22 October. The company's share capital stands at SEK 70,598,935.